Main Uses of Bricalin

Bricalin, which contains the active ingredient terbutaline, is a bronchodilator used to manage respiratory conditions characterized by airway obstruction. It is primarily utilized to relieve symptoms associated with asthma, chronic bronchitis, and emphysema. By acting on specific receptors in the lungs, it helps to relax the smooth muscles surrounding the airways, facilitating easier breathing.

Asthma Management

In patients with asthma, the airways can become inflamed and constricted in response to various triggers. Bricalin is used to provide rapid relief during acute episodes of bronchospasm, often referred to as asthma attacks. It helps to quickly open the airways, alleviating symptoms such as wheezing, shortness of breath, and chest tightness.

Chronic Obstructive Pulmonary Disease (COPD)

For individuals with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, Bricalin helps manage persistent respiratory difficulties. In these conditions, the airflow is often restricted due to long-term lung damage or excess mucus production. Bricalin assists in maintaining more open passages, which can improve daily physical activity levels and overall respiratory comfort.

Benefits of Treatment

Rapid Symptom Relief

One of the primary benefits of Bricalin is its ability to act quickly. When inhaled or administered during an acute respiratory event, it begins to relax the bronchial muscles within minutes. This rapid onset is essential for restoring normal breathing patterns during sudden bouts of breathlessness.

Improved Airflow and Exercise Tolerance

By reducing airway resistance, Bricalin improves the volume of air that can be inhaled and exhaled. For many patients, this leads to an increase in exercise tolerance, allowing them to engage in physical activities that might otherwise be difficult due to respiratory limitations.

Management of Reversible Airway Obstruction

Bricalin is specifically effective for conditions involving reversible airway obstruction. Unlike permanent lung damage, the constriction addressed by this medication is temporary and responsive to treatment, allowing for significant improvement in lung function during the period the medication is active.

Who can and cannot use Bricalin?

Official regulatory documentation strictly defines the population eligibility for Bricalin (Terbutaline sulfate), classifying patient groups into those permitted, those restricted, and those absolutely contraindicated.

Absolute Contraindications

Bricalin must not be used by individuals with a documented hypersensitivity to Terbutaline sulfate or any related sympathomimetic amines. Oral Bricalin is strictly contraindicated for the treatment or prevention of preterm labor (tocolysis). The injectable form is also prohibited for prolonged use exceeding 48–72 hours and is contraindicated in cases of specific hazardous maternal or fetal conditions, such as severe preeclampsia or hypertrophic cardiomyopathy.

Age and Conditional Eligibility

For the treatment of bronchospasm, oral Bricalin is generally restricted to patients 12 years of age and older; use in children younger than 12 is not recommended by regulators. The medicine requires conditional use with caution in patients with pre-existing comorbidities, including cardiovascular disorders (like ischemic heart disease or hypertension), diabetes mellitus, and hyperthyroidism. Furthermore, the tablet and powder forms are ineligible for individuals with rare hereditary sugar intolerances (e.g., total lactase deficiency).

Interactions with other medicines and products

The official regulatory documents for Bricalin establish several critical interaction constraints, primarily defined by pharmacodynamic effects and exposure modification.

• Beta-Blockers (including eye drops) may inhibit the effect of Bricalin on the lungs, which can lead to severe bronchospasm in asthmatic patients due to antagonism of pulmonary effects. This combination is generally discouraged.
• The co-administration of other Sympathomimetic Agents is not recommended due to the potential for a deleterious combined effect on the cardiovascular system.
• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the vascular action of Bricalin, necessitating extreme caution during co-use or within 2 weeks of their discontinuation. This establishes a mandatory timing separation rule.
• Non-Potassium-Sparing Diuretics (such as loop or thiazide diuretics), Xanthine Derivatives, and Corticosteroids may worsen the hypokalemia that can result from beta2-agonist use.
• Food is documented to reduce the peak plasma concentration and impair the bioavailability of the oral tablet.
• Elderly patients may experience more significant interaction effects due to age-related changes in organ function, requiring additional caution.
• The use of oral Bricalin for acute or maintenance tocolysis (preterm labor) is a contraindicated combination as noted in the U.S. label, due to the risk of serious maternal cardiac complications.

Targeted Activation of beta2-Adrenergic Receptors

Bricalin (Terbutaline sulfate) modulates physiological systems governing smooth muscle tone through highly targeted pharmacodynamic mechanisms. This mechanism engages specialized beta2-adrenergic receptors (beta2-AR) located on the walls of the bronchial tubes, functioning as a selective agonist to initiate a specific intracellular signal. This direct binding to the receptor initiates the sequence that defines the resulting physiological effect.

---

Intracellular Second Messenger Cascade

The initial receptor activation triggers the cAMP second messenger cascade, which rapidly increases the concentration of cyclic AMP within the cell. This increase ultimately leads to the functional inhibition of the enzyme responsible for muscle contraction, resulting in a reduction of available intracellular calcium.

---

Physiological Consequence: Smooth Muscle Relaxation

The inhibition of the contraction mechanism results directly in the relaxation of bronchial smooth muscle. This action occurs concurrently with the stabilization of inflammatory cells, which restricts the exocytosis of substances (like histamine) that promote muscle contraction.

How Bricalin is Used

Bricalin, which contains the active compound Terbutaline sulfate, is administered according to specific protocols. The medication is available in multiple dosage forms, including oral tablets, a solution for subcutaneous (SC) injection, and formulations for inhalation. These forms allow for use in both long-term management and the immediate treatment of acute episodes.

---

Official Dosing and Frequency

The standard approach to using Bricalin is determined by the route of administration, with specific maximum limits. For oral use, the typical adult starting dose (ge 15 years) is 5 mg taken three times daily. These tablets are scheduled at approximately 6-hour intervals while the patient is awake, and the total dose does not exceed 15 mg per 24 hours. Adolescents (12–15 years) have a lower maximum dose of 7.5 mg per day.

For acute needs, the subcutaneous injection route utilizes a 0.25 mg dose, which may be repeated once after 15 to 30 minutes if necessary, with a maximum of 0.5 mg within a four-hour window.

---

Administration Requirements and Restrictions

The SC injection is administered into the lateral deltoid area. For certain patient populations, such as those with kidney impairment (GFR < 50 mL/min), a 50% dose reduction may be applied. Furthermore, there are specific procedural restrictions: Terbutaline tablets are not indicated for use in premature labor, and the injectable form is not intended for prolonged use (beyond 48–72 hours) in this context. If an oral dose is missed, the practice is to skip the dose if it is almost time for the next scheduled interval.

Bricalin (terbutaline) is a selective beta-2 adrenergic receptor agonist studied primarily for its role in respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Efficacy and Mechanism of Action

Clinical trials have evaluated Bricalin's ability to help prevent and relieve bronchospasm—the tightening of muscles around the airways. Research suggests that the compound acts by stimulating beta-2 receptors, which are predominant in the bronchial smooth muscle. This receptor stimulation leads to a relaxation of the muscles in the lungs, which is associated with an increased flow of air through the bronchial tubes.

Clinical Findings

Clinical data on Bricalin generally indicate a rapid onset of action following inhalation, with effects typically beginning within minutes. This quality has led to its classification as a reliever medication for acute symptoms. Studies comparing Bricalin's sustained-release formulations against immediate-release tablets have found comparable therapeutic effects, with the modified formulation being examined for potential improved patient adherence due to reduced dosing frequency.

Area of Evaluation	Key Findings from Studies
Symptom Change	Observed differences in outcomes compared to placebo in reducing wheezing and shortness of breath.
Long-Term Use	The need for increased frequency of use may indicate a worsening of the underlying respiratory condition.

Safety and Tolerability Observations

Bricalin is generally used with caution in individuals with certain pre-existing conditions, including cardiovascular disease, diabetes, and hyperthyroidism. The most commonly reported side effects in trials include tremor (shakiness), nervousness, and headache. Researchers also noted potential cardiac effects, such as increased heart rate and palpitations. Furthermore, the risk of hypokalemia (low potassium levels) has been observed in some patient groups using this class of medication.

Common questions about Bricalin (FAQ)

Q: How should I store this medication?

Official product information indicates that Bricalin should be stored at room temperature. It must be kept in its original packaging, away from heat, excessive moisture, and light. For safety, the medication must also be kept out of the reach of children.

Q: Can I take this medicine with alcohol?

Regulatory warnings state that the combination of Bricalin and alcohol is not recommended. Both the medicine and alcohol can cause central nervous system effects, such as dizziness and sleepiness. Combining them may increase the risk of these effects.

Q: Does it make you sleepy?

According to official drug information, dizziness and somnolence (drowsiness or sleepiness) are common side effects reported with this medication. These effects may be more noticeable when beginning treatment or when the dosage is adjusted.

Q: Is it safe long-term?

Clinical trials for this medication include data from long-term use. However, regulatory warnings note a potential for dependence and misuse of Bricalin. Healthcare providers are advised to regularly evaluate the ongoing need for this treatment during periods of long-term use.

Q: Can children 2 years old use it?

Official prescribing information indicates that Bricalin is approved in some regions for use as an add-on therapy for partial-onset seizures in children as young as 1 month old. The use of this medication for other conditions in children is typically not included in the official label indication.

How to Store and Dispose of Bricalin?

Bricalin (Terbutaline sulfate) requires specific conditions to maintain its integrity and efficacy.

---

Storage Requirements

Temperature and Protection: Tablets must be stored at 20 C to 25 C and not above 30 C for inhalation forms. All forms must be protected from light and excessive moisture, and tablets must not be frozen. The medicine must always be stored out of the reach and sight of children.

Container and Stability: The product should be kept in a closed container or the original packaging. Certain multi-dose preparations have time limits: for example, an opened single nebulizer unit must be used within 24 hours.

---

Disposal Instructions

Expired or unused Bricalin should not be disposed of in household waste or wastewater. Disposal must be carried out in accordance with local requirements for pharmaceutical waste. Patients must consult a healthcare professional regarding proper disposal methods.